April 3, 2013
/PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in adoption of its CyberKnife® and TomoTherapy® Systems in
Accuray has expanded its installed base in the EIMEA region; Accuray radiation therapy systems have been used to treat more than 45,000 patients in EIMEA, further positioning the company as a global leader in precise, innovative radiation oncology.
The World Health Organization (WHO)
World Cancer Report 2014
revealed that the cancer burden is growing at an alarming pace, with the number of annual new cancer cases expected to reach 22 million by 2035, a substantial increase from the current rate of 14 million new cases per year.
is a region showing consistent and sustained growth for Accuray, with a high number of treatment centers that have two CyberKnife Systems at the same location, including
Erasmus MC - Daniel den Hoed Cancer Center
Ospedale Civile San Bortolo
Centro Diagnostico Italiano (CDI)
) as examples. Centers with at least one CyberKnife and one TomoTherapy System are also growing, including
Oscar Lambret Cancer Center
Antoine Lacassagne Cancer Center
Berard Cancer Center
Francois Baclesse Cancer Center
Charite University Hospital
Gliwice University Hospital
) as examples.
Additional 2013 EIMEA growth highlights include:
- The first CyberKnife® M6™ Series installations in France in the public and private sectors (Centre Eugene Marquis, Rennes, and Centre Hartmann, Levallois-Perret)
- The first CyberKnife M6 Series installation in Luxembourg
- The first CyberKnife System installation in Ireland
- The first TomoTherapy® H™ Series installation in Sri Lanka
- The first TomoTherapy installation in Greece (Iatropolis) making it the only center country-wide to offer both CyberKnife and TomoTherapy treatment
- The first TomoTherapy System installation in Russia
"The CyberKnife and TomoTherapy Systems are widely recognized by the global oncology community as precise, innovative tumor treatments covering the full spectrum of radiation oncology cases," said Lionel Hadjadjeba, general manager for EIMEA and senior vice president international business at Accuray. "These installation milestones reflect the increased adoption of our technologies throughout the world as we strive to optimize cancer care and enhance patient quality of life."